A5086986826- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Hematological disorders and diagnostics
- Liver Disease Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Metabolism and Genetic Disorders
- Acute Lymphoblastic Leukemia research
- Cancer Research and Treatments
- Gastrointestinal Tumor Research and Treatment
- Cutaneous lymphoproliferative disorders research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Zebrafish Biomedical Research Applications
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Cerebrovascular and genetic disorders
- Fungal Plant Pathogen Control
- Acute Myocardial Infarction Research
- RNA Interference and Gene Delivery
- Ubiquitin and proteasome pathways
- Energy and Environmental Systems
Tokyo-Kita Medical Center
2018-2024
International Myeloma Foundation
2023
Japan Association for Development of Community Medicine
2022
National Center for Global Health and Medicine
2010-2014
Chubu Rosai Hospital
2014
The University of Tokyo
2002-2011
Oita Medical Center
1992
Abstract Transcription factor AML1/Runx1, initially isolated from the t(8;21) chromosomal translocation in human leukemia, is essential for development of multilineage hematopoiesis mouse embryos. AML1 negatively regulates number immature hematopoietic cells adult hematopoiesis, whereas it required megakaryocytic maturation and lymphocytic development. However, remains yet to be determined how contributes homeostasis stem (HSCs). To address this issue, we analyzed detail HSC function absence...
Evi‐1 is a zinc‐finger transcriptional factor whose inappropriate expression leads to leukemic transformation in mice and humans. Recently, it has been shown that regulates proliferation of hematopoietic stem/progenitor cells at embryonic stage via GATA‐2 up‐regulation; however, detailed mechanisms underlying Evi‐1‐mediated early hematopoiesis are not fully understood. We therefore evaluated potential mutants using cultivation system murine para‐aortic splanchnopleural (P‐Sp) regions, found...
Abstract Polymerase chain reaction (PCR) is a sensitive method for detection of Aspergillus DNA in bronchoalveolar lavage fluid, but it has not yet been able to distinguish infection from contamination. We have established technique quantify using real‐time PCR resolve this problem, and we report herein successful application diagnose invasive pulmonary aspergillosis by comparing the amount bronchial fluid an affected area that unaffected area. This novel tool will provide rapid, sensitive,...
The p210 Bcr/Abl and p190 fusion oncoproteins are known to cause chronic myelogenous leukemia (CML) acute lymphoblastic (ALL). phosphorylates several proteins that can lead leukemogenesis. Crk‐associated substrate lymphocyte type (Cas‐L)/human enhancer of filamentation‐1 (HEF1)/neural precursor cell expressed, developmentally down‐regulated 9 (NEDD9) is an adapter protein at focal adhesions be associated with solid tumor metastasis. has also been reported tyrosine phosphorylated by . We...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy affecting multiple sites, most commonly the skin. About 10-20% of BPDCN cases are accompanied by neoplasms. A 71-year-old male was diagnosed with chronic myeloid leukemia in phase (CML-CP) 11 years prior (at 60 age), and dasatinib treatment initiated. major molecular response (MMR) achieved 18 months after diagnosis, (MR)
Objective Although R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is a standard therapy for diffuse large B-cell lymphoma (DLBCL), the optimal dose elderly patients remains unclear. Methods Patients We retrospectively verified our dose-attenuation system implemented from 2005 DLBCL patients. Among 115 treated during 2001-2010, 33 2001-2005 received doses adjusted according to physicians' decisions (PHY group). Eighty-two after unified (UNI aged <60, 60-69,...
Abstract A male patient had a relapse of myelodysplastic syndrome (MDS) 2 years after BMT from female matched unrelated donor. Conventional cytogenetics, FISH, and short‐tandem repeat chimerism analysis proved donor origin. He underwent reduced‐intensity conditioning with fludarabine busulfan, since he impaired renal, liver, pulmonary functions. Chimerism on day 28 the second showed mixed first donors, which later turned to full second‐donor 60. developed grade II acute GVHD skin...
Objective Currently, treatment of relapsed or refractory multiple myeloma is challenging. Although bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide (VTD-PACE), a potent combination proteasome inhibitor, immunomodulatory drug, and conventional chemotherapeutics, widely used regimen, its efficacy safety are unclear. Methods We retrospectively analyzed the clinical data 35 patients treated with VTD-PACE. Results The overall response rate was 65.7% (complete...
Extramedullary disease (EMD) is known to be associated with chemoresistance and poor prognosis in multiple myeloma (MM); however, the mechanisms of its development are not fully understood. Elucidating mechanism EMD therapeutic targeting would greatly contribute further improvement treatment outcome patients MM. Here, we show that bone marrow stroma cell-derived hyaluronan (HA) elicits homophilic interactions MM cells by binding surface CD44, especially long-stretch variants, under...
Background: The aim of this study was to evaluate prognostic impact insulin treatment and glucose control status on cardiovascular outcomes in diabetic patients after elective coronary intervention using drug-eluting stents (DES). Methods: A total 198 consecutive undergoing percutaneous (PCI) with DES Chubu Rosai Hospital from October 2005 March 2008 were enrolled. median HbA1c value the 7.5%. Patients divided into four groups based presence or absence at baseline (<7.5% ≧7.5%). endpoint...
Here we present the case of a 50-year-old woman with chronic myeloid leukemia who received nilotinib as initial treatment. After about 2 years therapy, she developed headache, blurred vision, impaired consciousness, and marked hypertension. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, strongly suspected to be vascular adverse event caused by nilotinib. Nilotinib withheld patient treated antihypertensive drugs under ventilator management. Her symptoms resolved quickly....